Catalent appoints first President of Asia Pacific
9 September 2013 | By Catalent Pharma Solutions
Catalent Pharma Solutions has named David Heyens in the new role of President of Catalent Asia Pacific...
List view / Grid view
News
Merck announces FDA acceptance of New Drug Application for investigational fertility treatment
9 September 2013 | By Merck
Merck announced that the NDA for its investigational fertility treatment, corifollitropin alfa, has been accepted for standard review by the U.S. FDA...
Biogen Idec and Isis Pharmaceuticals announce strategic collaboration to advance treatment of neurological disorders
9 September 2013 | By Biogen Idec
Biogen Idec and Isis Pharmaceuticals, Inc. announced that the companies have entered into a broad, multi-year collaboration...
Phase III results: Once daily olodaterol* Respimat® provides effective and sustained improvements in lung function in patients with COPD1-3
9 September 2013 | By Boehringer Ingelheim
Data from two 48 week Phase III studies involving more than 3,000 patients...
New Phase III data presented for first time demonstrate tiotropium Respimat® significantly improves lung function and provides sustained bronchodilation in asthma patients who remain symptomatic despite ICS treatment
9 September 2013 | By
In patients with symptomatic asthma despite moderate-dose maintenance ICS therapy, the addition of tiotropium Respimat® significantly improves lung function and provides sustained bronchodilation over 24 hours.1
Landmark TIOSPIRTM trial reinforces importance of SPIRIVA® in both available formulations as the world’s leading maintenance therapy for chronic obstructive pulmonary disease (COPD)
9 September 2013 | By Boehringer Ingelheim
TIOSPIR™, with over 17,000 COPD patients included and one of the largest international COPD trials ever conducted...
Merck and Israel’s Maccabi Healthcare to leverage unique real-world database to inform novel health approaches
9 September 2013 | By Merck
Merck and Maccabi Healthcare Services are starting a new, multi-year agreement...
Novartis data presented at ERS showcases once-daily COPD portfolio and further demonstrates efficacy of Ultibro® Breezhaler® (QVA149)
8 September 2013 | By Novartis
Novartis announced new analyses of data for once-daily Ultibro® Breezhaler®...
Takeda’s new investigational drug Vedolizumab granted priority review status by FDA for ulcerative colitis
6 September 2013 | By Takeda
FDA has granted Priority Review status for the Biologics License Application (BLA) for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis...
Novartis announces global research collaboration with Regenerex, leveraging a novel cell platform to broaden presence in the cell therapy space
6 September 2013 | By
Research collaboration advances company goal to deliver an innovative portfolio of novel cell therapy therapeutics for conditions with a high unmet need...
Capsugel to acquire Bend Research
5 September 2013 | By Capsugel
Capsugel and Bend Research have entered into a definitive agreement for Capsugel to acquire Bend Research as part of its DFS business unit...
The investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoint in Phase III melanoma clinical trial
5 September 2013 | By GlaxoSmithKline
In line with the Independent Data Monitoring Committee’s unanimous recommendation, GSK will continue the DERMA trial until the second co-primary endpoint is assessed...
Merck’s Durham site receives U.S. FDA licensure for varicella bulk
4 September 2013 | By Merck
Merck has received approval from the U.S. FDA to manufacture bulk varicella at the company’s site in Durham...
Novartis marks 30 year anniversary in transplantation and reinforces continued commitment to organ recipients at ESOT congress
4 September 2013 | By Novartis
Novartis reaffirms continued innovation in transplant during anniversary year of breakthrough therapy, ciclosporin...
AstraZeneca initiates Phase III clinical programme for olaparib, a treatment in development for patients with BRCA mutated ovarian cancer
4 September 2013 | By AstraZeneca
As a result of the initiation of this programme, a pre-tax impairment charge of $285 million will be reversed and the asset restored to our balance sheet in the third quarter of 2013...
